[1] Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer. 2010; 29(5): 517-26.
[2] van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012; 119(4): 924-32.
[3] Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013; 11(2): 223-33.
[4] Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res. 2018; 164 Suppl 1: S54-S61.
[5] Chen YP, Chen C, Mai ZY, Gao J, Shen LJ, Zhao BC, et a1. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 2015; 9(3): 1458-1466.
[6] He SS, Wang Y, Yang L, Chen HY, Liang SB, Lu LX, et a1. Plasma Fibrinogen Correlates with Metastasis and is Associated with Prognosis in Human Nasopharyngeal Carcinoma. J Cancer. 2017; 8(3): 403-409.
[7] Chen WH, Tang LQ, Wang FW, Li CP, Tian XP, Huang XX, et a1. Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer. 2014; 14: 583.
[8] Chen YP, Zhao BC, Chen C, Shen LJ, Gao J, Mai ZY, et a1. Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients. Chin J Cancer. 2015; 34(3): 137-46.
[9] Huang XD, Yi JL, Gao L, Xu GZ, Jin J, Yang WZ, et a1. Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi. 2007; 29(3): 197-201.
[10] You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, et a1. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics. 2017; 7(8): 2314-2324.
[11] Wang F, Sun Q, Jiang C, Liu T, Rihito A, Masoto S, et a1. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis. J Cancer. 2018; 9(3): 594-603.
[12] Li Z, Li Y, Yan S, Fu J, Zhou Q, Huang X, et a1. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma. Onco Targets Ther. 2017; 10: 5445-5458.
[13] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et a1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-47.
[14] Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie. 2012; 32(2): 95-104.
[15] Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer. Ann N Y Acad Sci. 2017; 1404(1): 27-48.
[16] Tas F, Kilic L, Serilmez M, Keskin S, Sen F, Duranyildiz D. Clinical and prognostic significance of coagulation assays in lung cancer. Respir Med. 2013; 107(3): 451-7.
[17] Zhu M, Dai Y, Gao F, Xu C, Chen L, Xu Y, et a1. Correlations of coagulation indexes and inflammatory changes with the prognosis of lung cancer complicated with thromboembolic disease. J BUON. 2019; 24(2): 585-590.
[18] Zhang K, Gao HF, Mo M, Wu CJ, Hua YQ, Chen Z, et a1. A novel scoring system based on hemostatic parameters predicts the prognosis of patients with advanced pancreatic cancer. Pancreatology. 2019; 19(2): 346-351.
[19] Lee S, Huh SJ, Oh SY, Koh MS, Kim SH, Lee JH, et a1. Clinical significance of coagulation factors in operable colorectal cancer. Oncol Lett. 2017; 13(6): 4669-4674.
[20] Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su JR, et a1. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer. 2017; 8(11): 2079-2087.
[21] Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013; 33(5).
[22] Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014; 229(8): 1005-15.
[23] Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018; 11(1): 125.
[24] Holgersson G, Bergstrom S, Hallqvist A, Liv P, Nilsson J, Willen L, et a1. The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy. Neoplasma. 2017; 64(6): 909-915.
[25] Wang YH, Kang JK, Zhi YF, Zhang Y, Wang ZQ, Zhou Q, et a1. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis. Int J Surg., 2018; 53: 304-311.
[26] Wang H, Gao J, Bai M, Liu R, Li H, Deng T, et a1. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2014; 25(5): 382-7.
[27] Lee S, Huh SJ, Oh SY, Koh MS, Kim SH, Lee JH, et a1. Clinical significance of coagulation factors in operable colorectal cancer. Oncol Lett. 2017; 13(6): 4669-4674.
[28] Wen J, Yang Y, Ye F, Huang X, Li S, Wang Q, et a1. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast. 2015; 24(6): 745-50.
[29] Zhao K, Deng H, Qin Y, Liao W, Liang W. Prognostic significance of pretreatment plasma fibrinogen and platelet levels in patients with early-stage cervical cancer. Gynecol Obstet Invest. 2015; 79(1): 25-33.
[30] Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013; 34(1): 39-45.
[31] Xie X, Zeng X, Cao S, Hu X, Shi Q, Li D, et a1. Elevated pretreatment platelet distribution width and platelet count predict poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017; 8(62): 106089-106097.
[32] Lan M, Chen C, Huang Y, Mao M, Han F, Liao J, et a1. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Oncotarget. 2016; 7(29): 46242-46252.
[33] Tang LQ, Chen QY, Guo SS, Chen WH, Li CF, Zhang L, et a1. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer. 2014; 111(6): 1102-11.
[34] Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA, Bratman SV, et a1. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. Int J Radiat Oncol Biol Phys. 2017; 98(5): 996-1001.